The prevalence of atrial fibrillation (AFib) in β-thalassemia major (β-TM) patients has increased in the last few years, reaching up to 33.0%. Several factors may drive this value to even more in the next few years. We summarized the main challenges in the management and therapy of AFib in this very specific group of patients.
Atrial fibrillation in β-thalassemia Major Patients: Diagnosis, Management and Therapeutic Options
Barbero U;Fornari F;Gaglioti CM;Anselmino M;Piga A.
Last
2018-01-01
Abstract
The prevalence of atrial fibrillation (AFib) in β-thalassemia major (β-TM) patients has increased in the last few years, reaching up to 33.0%. Several factors may drive this value to even more in the next few years. We summarized the main challenges in the management and therapy of AFib in this very specific group of patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Barbero LHEM-42-2-2018-0070-REVISED-3rd version_UB.docx
Accesso riservato
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
34.8 kB
Formato
Microsoft Word XML
|
34.8 kB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
|
Barbero LHEM-42-2-2018-0070-REVISED-3rd version_UB.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
51.71 kB
Formato
Adobe PDF
|
51.71 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
